Brief: Hookipa Pharma Announces Positive Preliminary Phase 2 Data On HB-200 In Combination With Pembrolizumab In Patients With HPV16+ Head And Neck Cancers

Hookipa Pharma

31/05/2023 22:11

May 31 (Reuters) - HOOKIPA Pharma Inc  HOOK.O :
    * HOOKIPA PHARMA ANNOUNCES POSITIVE PRELIMINARY PHASE 2 DATA
ON
HB-200 IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH HPV16+
HEAD AND NECK CANCERS
    * HOOKIPA PHARMA INC- PREPARING TO START PIVOTAL TRIAL OF
HB-200
IN COMBINATION WITH PEMBROLIZUMAB IN 2024
    * HOOKIPA PHARMA - RESULTS FROM PHASE 1/2 STUDY SHOWED THAT
HB-200
WAS GENERALLY WELL TOLERATED AMONG 132 PATIENTS TREATED
    * HOOKIPA PHARMA INC- SAFETY PROFILE SIMILAR FOR PATIENTS
WHO
RECEIVED HB-200 MONOTHERAPY OR HB-200 IN COMBINATION WITH
PEMBROLIZUMAB IN PHASE 1/2 STUDY
    * HOOKIPA PHARMA - RESULTS FROM PHASE 1/2 STUDY SHOWED THAT
ONLY
7% OF PATIENTS SHOWED SERIOUS ADVERSE EVENTS RELATED TO
TREATMENT WITH HB-200

Source text for Eikon:  ID:nGNX1NxFbj 
Further company coverage:  HOOK.O 

 ((Reuters.Briefs@thomsonreuters.com;))